首页 | 本学科首页   官方微博 | 高级检索  
     


Immunotherapy for the Treatment of Urothelial Carcinoma
Authors:Nicholas M. Donin  Andrew T. Lenis  Stuart Holden  Alexandra Drakaki  Allan Pantuck  Arie Belldegrun  Karim Chamie
Affiliation:Department of Urology, Institute of Urologic Oncology (NMD, SH, AD, AP, AB, KC), David Geffen School of Medicine at UCLA, Los Angeles, California;Department of Medicine, Division of Hematology and Oncology (AD), David Geffen School of Medicine at UCLA, Los Angeles, California;Jonsson Comprehensive Cancer Center (AD, AP, AB, KC), University of California, Los Angeles, California
Abstract:
Keywords:BCG vaccine  cancer vaccines  cell cycle checkpoints  immunotherapy  urologic neoplasms  AE  adverse event  APC  antigen presenting cell  BCG  bacillus Calmette-Guérin  CAR  chimeric antigen receptor  CIS  carcinoma in situ  CTA  cancer testis antigen  CTLA-4  cytotoxic T-lymphocyte antigen 4  FDA  U.S. Food and Drug Administration  HLA  human leukocyte antigen  IFN  interferon  IHC  immunohistochemistry  MCNA  Mycobacterium phlei cell wall nucleic acid complex  MHC  major histocompatibility complex  NK  natural killer  NMIBC  nonmuscle invasive bladder cancer  NSCLC  nonsmall cell lung cancer  RB  retinoblastoma  RCC  renal cell carcinoma  TCR  T-cell receptor  TLR  Toll-like receptor  TUR  transurethral resection  UC  urothelial cancer
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号